Mortality difference from Klebsiella aerogenes vs Enterobacter cloacae bloodstream infections

References

1. Wilson BM, El Chakhtoura NG, Patel S, Saade E, Donskey CJ et al. Carbapenem-resistant Enterobacter cloacae in patients from the US Veterans Health Administration, 2006-2015. Emerg Infect Dis 2017; 23:878–880 [View Article]
   [Google Scholar]
2. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998-2007. Clin Microbiol Infect 2011; 17:539–545 [View Article] [PubMed]
   [Google Scholar]
3. Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E et al. A multinational, preregistered cohort study of β-Lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2016; 60:4159–4169 [View Article] [PubMed]
   [Google Scholar]
4. Huh K, Kang C-I, Kim J, Cho SY, Ha YE et al. Risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporin-resistant Enterobacter species in adults with cancer. Diagn Microbiol Infect Dis 2014; 78:172–177 [View Article] [PubMed]
   [Google Scholar]
5. Song EH, Park K-H, Jang E-Y, Lee EJ, Chong YP et al. Comparison of the clinical and microbiologic characteristics of patients with Enterobacter cloacae and Enterobacter aerogenes bacteremia: a prospective observation study. Diagn Microbiol Infect Dis 2010; 66:436–440 [View Article] [PubMed]
   [Google Scholar]
6. Wesevich A, Sutton G, Ruffin F, Park LP, Fouts DE et al. Newly named Klebsiella aerogenes (formerly Enterobacter aerogenes) is associated with poor clinical outcomes relative to other Enterobacter species in patients with bloodstream infection. J Clin Microbiol 2020; 58:e00582-20 [View Article]
   [Google Scholar]
7. Jeon M, Huh K, Ko J-H, Cho SY, Huh HJ et al. Difference in the clinical outcome of bloodstream infections caused by Klebsiella aerogenes and Enterobacter cloacae complex. Open Forum Infect Dis 2021; 8:fab390 [View Article]
   [Google Scholar]
8. Álvarez-Marín R, Lepe JA, Gasch-Blasi O, Rodríguez-Martínez JM, Calvo-Montes J et al. Clinical characteristics and outcome of bacteraemia caused by Enterobacter cloacae and Klebsiella aerogenes: more similarities than differences. J Glob Antimicrob Resist 2021; 25:351–358 [View Article] [PubMed]
   [Google Scholar]
9. Tindall BJ, Sutton G, Garrity GM. Enterobacter aerogenes Hormaeche and Edwards 1960 (Approved Lists 1980) and Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980) share the same nomenclatural type (ATCC 13048) on the Approved Lists and are homotypic synonyms, with consequences for the name Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980). Int J Syst Evol Microbiol 2017; 67:502–504 [View Article]
   [Google Scholar]
10. Davin-Regli A, Lavigne JP, Pagès JM. Enterobacter spp.: update on taxonomy, clinical aspects, and emerging antimicrobial resistance. Clin Microbiol Rev 2019; 32:e00002-19 [View Article] [PubMed]
    [Google Scholar]
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–383 [View Article] [PubMed]
    [Google Scholar]
12. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130–1139 [View Article] [PubMed]
    [Google Scholar]
13. Wang M, Earley M, Chen L, Hanson BM, Yu Y et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis 2022; 22:401–412 [View Article] [PubMed]
    [Google Scholar]
14. Paterson DL, Ko W-C, Von Gottberg A, Mohapatra S, Casellas JM et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140:26–32 [View Article] [PubMed]
    [Google Scholar]
15. Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for transplantation and cellular therapy. Biol Blood Marrow Transplant 2020; 26:1247–1256 [View Article] [PubMed]
    [Google Scholar]
16. Giannella M, Pascale R, Toschi A, Ferraro G, Graziano E et al. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect 2018; 24:1077–1083 [View Article] [PubMed]
    [Google Scholar]
17. Wiggers JB, Xiong W, Daneman N. Sending repeat cultures: is there a role in the management of bacteremic episodes? (SCRIBE study). BMC Infect Dis 2016; 16:286 [View Article]
    [Google Scholar]
18. Richter SS, Sercia L, Branda JA, Burnham C-AD, Bythrow M et al. Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the VITEK MS system. Eur J Clin Microbiol Infect Dis 2013; 32:1571–1578 [View Article] [PubMed]
    [Google Scholar]
19. bioMérieux, Inc bioMérieux Connection Durham. NC: bioMérieux, Inc; 2012Aug https://www.biomerieux-usa.com/news/connection-archive
20. bioMérieux, Inc bioMérieux Connection Durham. NC: bioMérieux, Inc; 2011Jul https://www.biomerieux-usa.com/news/connection-archive
21. Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J. Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae. J Clin Microbiol 2011; 49:1048–1057 [View Article] [PubMed]
    [Google Scholar]
22. Mushtaq A, Chasan R, Nowak MD, Rana M, Ilyas S et al. Correlation between identification of β-lactamase resistance genes and antimicrobial susceptibility profiles in gram-negative bacteria: a laboratory data analysis. Microbiol Spectr 2022; 10:e0148521 [View Article] [PubMed]
    [Google Scholar]
23. CLSI Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed.
24. Zaharatos GJ, Dascal A, Miller MA. Discordant carbapenem susceptibility in Methylobacterium species and its application as a method for phenotypic identification. J Clin Microbiol 2001; 39:2037–2038 [View Article] [PubMed]
    [Google Scholar]
25. Kim YJ, Kim SI, Kim YR, Hong KW, Wie SH et al. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol Infect 2012; 140:137–145 [View Article] [PubMed]
    [Google Scholar]
26. Kang C-I, Kim S-H, Park WB, Lee K-D, Kim H-B et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760–766 [View Article] [PubMed]
    [Google Scholar]
27. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D et al. Infectious diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis 2022; 74:2089–2114 [View Article] [PubMed]
    [Google Scholar]
28. Octaria R, Rebeiro PF, Kainer MA. Methodologic considerations for small cohort studies. Clin Infect Dis 2019; 69:1644 [View Article]
    [Google Scholar]
29. Mehta CR, Patel NR. Exact logistic regression: theory and examples. Stat Med 1995; 14:2143–2160 [View Article] [PubMed]
    [Google Scholar]
30. Young BE, Fong S-W, Chan Y-H, Mak T-M, Ang LW et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet 2020; 396:603–611 [View Article] [PubMed]
    [Google Scholar]